Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO an...

by Cohen C., Molina J., Cahn P., Clotet B., Fourie J., Grinsztejn B., Wu H., Johnson M., Saag M., Supparatpinyo K., Crauwels H., Lefebvre E., Rimsky L., Vanveggel S., Williams P., Boven K.
Published 2017